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ABSTRACT 
UTI is the common bacterial infectious disease in both hospital and community practice with a high rate of morbidity and 
economic cost associated with treatment. It has been estimated that 150 million people were infected with UTI per annum. The study 
is to analyze the bacteriological and antibiotic susceptibility pattern in lower UTI in a specific geographical region and to analyze the 
effectiveness of Fosfomycin in the treatment of lower UTI from urology outpatient department of a tertiary care hospital. Females 
were more prevalent for urinary tract infection and the most prevalent organism is found to be E.coli, followed by pseudomonas 
aeruginosa. The antibiotic sensitivity pattern of both gram negative and gram positive cocci revealed maximum sensitivity for 
fosfomycin (98%), followed by imipenem (79%). The study shows that uropathogens have shown decreased susceptibility to most of 
the available antibiotics for the treatment of UTI while fosfomycin shows high sensitivity to most of the uropathogens isolated. Our 
findings underline the important role of fosfomycin in the antibacterial armamentarium for the treatment of UTI. We conclude that 
Fosfomycin is a good alternative in the treatment of UTI. 
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INTRODUCTION 
UTIs encompass a spectrum of clinical entities 
ranging in severity from asymptomatic infection to acute 
pyelonephritis with sepsis. Women have more UTIs than men 
probably because of anatomic and physiologic differences [1]. 
Nearly 1 in 3 women will have had at least one episode of UTI 
requiring antimicrobial therapy by the age of 24 years [2]. E. coli 
is a frequently isolated pathogen, but it accounts for less than 
50% of infections. Other frequently isolated organisms include 
Proteus spp., K. pneumoniae, Enterobacter spp., P. aeruginosa, 
staphylococci, and enterococci [3]. 
E. coli resistance is continuing to increase, therefore it 
is imperative for the healthcare professional to be familiar with 
the resistance trends in their geographical area when 
prescribing therapy [4]. Drug treatment of a lower UTI often is 
started before C&S results are known because the most 
probable infecting organism and its sensitivity to antibiotics can 
be predicted [5]. The choice of antimicrobial agents should 
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DOI: 
preferably consider the urinalysis result, which allow for 
pathogen identification, in addition to antimicrobial 
susceptibility testing that indicates the susceptibility of 
microorganisms to specific group of antimicrobials [6]. 
The alarmingly increasing antibiotic resistance rates 
reported among both Gram positive and Gram negative 
pathogens necessitate the implementation of alternative 
treatment strategies. In view of the rather limited availability of 
novel antimicrobial agents, the re-evaluation of older antibiotic 
agents seems to be an appealing option. Fosfomycin, an old and 
rather decommissioned antibiotic, which was previously used 
mainly as oral (PO) treatment for uncomplicated urinary tract 
infections (UTIs), currently attracts clinicians’ interest 
worldwide. Particularly, the reported activity against pathogens 
with advanced resistance suggests that this antibiotic may 
provide a useful option for the treatment of patients with these 
difﬁcult-to-treat-infections [7]. 
METHODOLOGY 
A prospective observational study was conducted at 
department of urology at Karuna Medical College Hospital, 
Palakkad, Kerala for 6 months - between from November 2017 
to April 2018. Ethical approval for this study (SDAT / KMC/12-
2017/84) was provided by Institutional Ethics Committee in 
Karuna Medical College, which permits and confirms that the 
institute gives approval to release the data. 
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Bacterial Isolates: 
The present observational study was performed on 
UTI cases who were referred to outpatient department of 
urology, Karuna medical college hospital, Palakkad  from 
November to April .Patients those who were clinically 
diagnosed with UTI and those for whom urine microscopy 
culture and sensitivity has been ordered as a part of routine 
medical test were included in the study. Pediatric population of 
patients with UTI symptoms, patients with symptoms of acute 
pyelonephritis and female population on their menstrual phase, 
Urine specimen showing ESBL and MRSA were also excluded in 
the study.  A total of 107 clinical isolates were obtained from 
the urine specimens of patients with lower UTI.  Urine samples 
were obtained from the study subjects. UTI refers to the 
existence of microbial pathogens in the urinary tract and is 
defined as the growth of a single pathogen of > 105 colony-
forming units per millilitre (CFU/ml) from properly collected 
midstream urine specimens. Proper specimen collection was 
instructed to all patients. All samples were processed on Muller 
Hinton agar using calibrated loops. The inoculated plates were 
aerobically incubated at 370C for 48 hours. The specimen was 
considered positive and negative for UTI if a single organism is 
at a concentration of ≥ 105 CFU/ml and < 102 CFU/ml 
respectively. Negative cultures were maintained in incubator up 
to 2 days. Bacterial isolates were identified on the basis of their 
cultural and biochemical characteristics. Identification of gram 
positive isolates was performed by gram staining.   
Antibiotic Susceptibility Testing: 
Antibacterial susceptibility of isolates was tested by 
Kirby-Bauer disk diffusion .For gram-negative and gram- 
positive bacteria, following discs were tested with their 
respective concentration. The following antimicrobial agents 
were used in the study: amikacin, ampicillin, ampicillin-
sulbactam, azithromycin, cefotaxime, cefotaxime clavunalic 
acid, ceftazidime, ceftriaxone, cefuroxime, cotrimoxazole, 
doxycycline, fosfomycin, gentamycin , imipenem, levofloxacin, 
linezolid, meropenem, netilmycin, nitrofurantoin, norfloxacin, 
ofloxacin, piperacillin + tazobactam. Diameter of inhibition 
zones was measured after incubation at 350C for 18-24 hours, 
and data were reported as Sensitive, Intermediate and 
Resistant. All the collected data was analysed by the Graph pad 
prism version 7.0 by using one way ANOVA and p value < 0.05 
was consider as statistically significant. 
RESULTS AND DISCUSSION 
Urinary tract infection (UTI) is the most common and 
a serious health affecting problem both in community and 
hospital settings each year worldwide. It is the second most 
infection after respiratory tract infection [8]. This study was 
conducted with an objective to analyse the bacteriological 
pattern in lower UTI in a specific geographical area, to study the 
antibacterial susceptibility pattern, and to determine the 
effectiveness of oral fosfomycin, thus the proper selection of an 
empirical antibiotic for the treatment of lower UTI. Among the 
total number of patients, there is a higher frequency of culture 
positivity in females (65%) than in males (35%). Similar 
studies conducted by Rupinder Bakshi et al.,[9]
 
and Razak SK 
et al., [ 10 ]  which shows higher prevalence in females when 
compared to males. 
                 Out of the isolated organisms, the predominant 
organism E.coli is mostly affected in females as compared to 
male followed by pseudomonas species with higher frequency 
in males as compared to females which correlates with the 
study conducted by Ozlem Guneysel et al [11] which states that 
the most common pathogen isolated from the cultures in the 
study group was E.coli (93.4%). 
Table 1 shows that the Antibiotic sensitivity pattern of 
both gram negative bacilli and gram positive cocci revealed that 
the maximum sensitivity is for fosfomycin (98%) followed by 
imipenem (85.7%), nitrofurantoin (67%), meropenem (60.8%), 
netilmicin (59%) and cotrimoxazole (58.1%). The maximum 
resistance was seen against cefotaxime (62.2%), ampicillin 
(59.1%), cefuroxime (57.1%), norfloxacin(54.4%), ceftriaxone 
(54%), ceftazidime (52%) which correlates with study 
conducted by A. Acharya et al., [12] which shows that more than 
50% of common pathogens were resistant to ceftriaxone. 
The antimicrobial potency and spectrum for 23 
selected antimicrobial agents of different classes against the 6 
most frequent gram negative UTI pathogens and 2 frequent 
gram positive UTI pathogens are summarized in table 2 and 
table 3. Among most frequently isolated gram negative and 
gram positive pathogens, 98% were found to be highly sensitive 
to fosfomycin. 
                  E.coli showed high sensitivity to fosfomycin (97.4%) 
followed by imipenem (89.6%), nitrofurantoin (66.23%), 
Meropenem (61.03%), Cotrimoxazole (59.74%), Netilmycin 
(58.44). According to Supriya et al [13] susceptibility pattern 
showed, nitrofurantoin (62.5%), cefotaxime (58.7%), 
norfloxacin (44.9%), ampicillin (21.4%) and cotrimoxazole 
(18%). 
                  In our study fosfomycin was found to be most 
sensitive followed by imipenem, nitrofurantoin, cotrimoxazole, 
meropenem, gentamycin, netilmycin, and doxycycline. 
Amoxicillin clavulanic acid, erythromycin and polymyxin is 
found to be least sensitive.Here,  gram positive organism 
showed following sensitivity pattern fosfomycin in (100%), 
nitrofurantoin (83.3), ampicillin (50%), ofloxacin (50%), 
levofloxacin (50%). 
Table 4 shows the comparison of efficacy of 
fosfomycin, nitrofurantoin, cefotaxime and Ofloxacin with 
respect to zone of inhibition. It was done by using Graph Pad 
prism with One way – ANOVA in which the p- Value was found 
to be extremely significant with a value of <0.0001.. 
On taking the reports of 75 cases out of 100 cases, the 
effectiveness of Fosfomycin is much more compared to other 
antibiotics used in the treatment of lower UTI – from the culture 
and sensitivity study reports. This finding is analogous with the 
study conducted by Smitha et al [14] that concludes fosfomycin 
in a single 3-4 gram dose is as effective as 7 day regimen of 
nitrofurantoin for the treatment of uncomplicated lower UTI in 
women. 
Table 5 shows the zone of inhibition of Fosfomycin, 
Nitrofurantoin, Ofloxacin, and Cefotaxime for the 75 cases, 
where Nitrofurantoin, Ofloxacin and Cefotaxime are the other 
commonly prescribing antibiotics for lower UTI. 
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Table No. 1: Antibiotic sensitivity and resistance pattern of isolated organism in lower UTI 
ANTIBIOTIC S % I % R % 
AMIKACIN 37 37% 26 26%  36 36% 
AMPICILLIN 21 21% 19 19% 58 58% 
AMPICILLIN /SULBACTAM 41 41% 27 27% 30 30% 
AZITHROMYCIN 41 41% 27 27% 30 30% 
AZTREONAM 3 3% 0 0% 5 5% 
CEFOTAXIME 21 21% 16 16% 61 61% 
CEFOTAXIME CLAVULANIC ACID 33 33% 35 35% 24 24% 
CEFTAZIDIME 33 33% 14 14% 51 51% 
CEFTRIAXONE 18 18% 27 27% 53 53% 
CEFUROXIME 30 30% 12 12% 56 56% 
CIPROFLOXACIN 11 11% 5 5% 17 17% 
COTRIMOXAZOLE 57 57% 5 5% 36 36% 
DOXYCYCLINE 46 46% 21 21% 30 30% 
FOSFOMYCIN 98 98% 2 2% 0 0% 
GENTAMICIN 57 57% 14 14% 26 26% 
IMEPENEM 79 79% 3 3% 10 10% 
LEVOFLOXACIN 30 30% 22 22% 37 37% 
LINEZOLID 4 4% 0 0% 1 1% 
MEROPENEM 59 59% 10 10% 28 28% 
POLYMIXIN 1 1% 0 0% 2 2% 
NITROFURANTOIN 65 65% 12 12% 19 19% 
OFLOXACIN 38 38% 13 13% 47 47% 
PIPERACILLIN +TAZOBACTAM 33 33% 36 36% 24 24% 
VANCOMYCIN 2 2% 0 0% 0 0% 
ERYTHROMYCIN 0 0% 0 0% 1 1% 
AMOXYCILLIN CLAVULANIC ACID 0 0% 0 0% 1 1% 
NORFLOXACIN 27 27% 14 14% 49 49% 
NETILMYCIN 56 56% 15 15% 24 24% 
n=100; *S-Sensitive; *I-Intermediate; *R-Resistant 
Table No. 2: Antibiogram pattern of most frequently isolated gram negative urinary pathogens 
Antibiotics E .coli (n=77) Klebsiella 
species(n=3) 
Acineto 
bacter (n=4) 
Citrobacter 
(n=1) 
Pseudomonas 
species(n=6) 
Enterobacter 
(n=3) 
 S I R S I R S I R S I R S I R S I R 
Amikacin 29 21 27 0 0 3 3 1 0 1 0 0 2 2 2 1 1 1 
Ampicillin 14 20 43 0 0 3 0 2 2 0 0 1 0 0 4 1 1 1 
Ampicillin 
sulbactam 
35 19 23 0 2 1 2 1 1 0 0 1 1 2 3 2 1 0 
Azithromycin 18 20 36 2 0 1 0 2 2 1 0 0 3 0 2 0 2 1 
Aztreonam 0 0 4 0 0 0 0 0 0 0 0 0 2 0 0 0 1 0 
Cefotaxime 19 12 46 0 0 3 1 1 2 0 0 1 0 0 5 0 3 0 
Cefotaxime 
clavulanic acid 
25 8 18 0 1 0 3 1 0 0 0 1 2 0 2 0 1 0 
Ceftazidime 25 12 39 0 1 2 2 1 1 0 0 1 1 0 2 3 0 0 
Ceftriaxone 22 12 42 0 1 2 2 1 1 0 0 1 0 1 5 1 1 1 
Cefuroxime 24 11 42 0 0 3 4 0 0 0 0 1 0 0 6 1 1 1 
Cotrimoxazole 46 3 28 2 1 0 2 0 1 0 0 1 3 0 2 2 0 1 
Doxycycline 36 19 22 1 0 2 3 0 0 0 1 0 1 1 4 1 0 2 
Fosfomycin 75 2 0 3 0 0 4 0 0 1 0 0 6 0 0 3 0 0 
Gentamycin 43 13 18 3 0 0 2 0 2 1 0 0 3 0 2 1 0 1 
Imipenem 69 2 6 3 0 0 3 1 0 1 0 0 2 0 3 3 0 0 
Levofloxacin 21 20 31 0 0 3 0 2 1 1 0 0 3 0 2 3 0 0 
Linezolid 2 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Meropenem 47 10 20 1 0 2 3 0 1 1 0 0 2 0 3 3 0 0 
Netilmicin 45 13 18 2 1 0 2 0 2 1 0 0 3 0 3 2 1 0 
Nitrofurantoin 51 14 11 1 0 2 3 0 1 1 0 0 3 0 2 0 0 2 
Norfloxacin 20 14 38 0 0 3 3 1 0 1 0 0 2 0 3 3 0 0 
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Ofloxacin 26 12 38 0 0 3 2 1 1 1 0 0 3 0 3 3 0 0 
Piperacillin 
Tazobactam 
28 29 16 0 0 3 1 2 1 1 0 0 3 1 2 0 1 0 
*S-Sensitive;        *I-Intermediate;           *R-Resistant 
Table No. 3: Antibiogram pattern of most frequently isolated gram positive urinary pathogens 
Antibiotics Enterococcus species (n=4) Coagulase negative 
staphylococcus (n=2) 
S I R S I R 
Amikacin 0 2 2 1 0 0 
Ampicillin 3 0 1 0 0 0 
Ampicillin sulbactam 2 1 1 0 0 0 
Azithromycin 2 1 0 0 0 0 
Aztreonam 0 0 1 0 0 0 
Cefotaxime 2 1 1 0 0 0 
Cefotaxime clavulanic acid 3 0 0 0 0 0 
Ceftazidime 2 0 2 0 0 1 
Ceftriaxone 2 1 1 0 0 0 
Cefuroxime 1 0 3 0 0 0 
Cotrimoxazole 1 0 3 1 0 0 
Doxycycline 2 1 1 0 0 0 
Fosfomycin 4 0 0 2 0 0 
Gentamycin 2 1 1 0 0 0 
Imipenem 3 0 1 0 0 0 
Levofloxacin 3 0 0 0 0 0 
Linezolid 1 0 0 2 0 0 
Meropenem 2 0 2 0 0 0 
Netilmicin 1 1 2 0 0 0 
Nitrofurantoin 4 0 0 1 0 0 
Norfloxacin 1 0 2 0 0 0 
Ofloxacin 2 0 2 1 0 0 
Piperacillin Tazobactam 1 2 1 0 0 1 
*S-Sensitive        *I-Intermediate           *R-Resistant 
Table No. 4: Comparison of the efficacy of fosfomycin with other commonly prescribed antibiotics with respect to the zone 
of inhibition 
SL. No Fosfomycin 
ZOI  
Nitrofurantoin 
ZOI  
Cefotaxime 
ZOI  
Ofloxacin 
ZOI 
1 S S R I 
2 S S S R 
3 S R S R 
4 S S R R 
5 S S R R 
6 S S R R 
7 S R R S 
8 S R R S 
9 S R R S 
10 S S S S 
11 S R R I 
12 S S R R 
13 S I R R 
14 S S R S 
15 S I S S 
16 S S S S 
17 S S I S 
18 S S I R 
19 S S R R 
20 S S R R 
21 S I R R 
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22 S S S R 
23 S R R S 
24 S R S S 
25 S S S S 
26 S S R S 
27 S S S S 
28 S S R R 
29 S S R R 
30 S S R R 
31 S S R R 
32 S R R R 
33 S S R R 
34 S I S I 
35 S S S I 
36 S S R R 
37 S S I R 
38 S S I R 
39 S I R S 
40 S I I S 
41 S S R R 
42 S S R S 
43 S S S S 
44 S S R R 
45 S S R R 
46 S S S R 
47 S S R R 
48 S R I R 
49 S S S S 
50 S S R R 
51 S S R R 
52 S S I S 
53 S S R R 
54 S S I S 
55 S S I I 
56 S R R R 
57 S S I S 
58 S S R S 
59 S I S S 
60 S I R R 
61 S S I S 
62 S S S S 
63 S R R I 
64 S S R I 
65 S S R R 
66 S I R R 
67 S S R S 
68 S I R S 
69 S S I S 
70 S S R R 
71 S S R R 
72 S S R I 
73 S S R R 
74 S S I S 
75 S I R S 
 
Manufacture
r’s provided 
ZOI (mm) 
S I R S I R S I R S I R 
≥16 13-15 ≤12 ≥17 15-16 ≤14 ≥23 15-22 ≤14 ≥16 13-15 ≤12 
S – Sensitive;  I – Intermediate; R – Resistant 
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Table No. 5:  Comparison of the statistical parameters of the Antibiotics 
Antibiotics Mean Standard Deviation Standard Error of Mean 
Fosfomycin 29.96 3.54 0.3909 
Nitrofurantoin 17.85 4.104 0.4532 
Ofloxacin 13.46 5.84 0.6449 
Cefotaxime 12.95 7.501 0.8284 
Table No. 6: Comparison of the efficacy of Antibiotics with respect to Fosfomycin 
COMPARISON TEST SIGNIFICANCE P VALUE 
FOSFOMYCIN vs. NITROFURANTOIN **** <0.0001 
FOSFOMYCIN vs. CEFOTAXIME **** <0.0001 
FOSFOMYCIN vs. OFLOXACIN **** <0.0001 
 
It  shows  the  comparison  of  the  statistical  
parameters  such  as  mean,  median, standard deviation and 
standard error. These statistical parameters are obtained from 
graph pad prism version 7.0 using one way ANOVA method. 
The figure shows the comparison of the effectiveness of 
Fosfomycin with Nitrofurantoin, Ofloxacin, and Cefotaxime.  It  
reveals  that  fosfomycin  is  more  effective  as  compared  to  
other commonly prescribed antibiotics  followed  by  
Nitrofurantoin.  It shows a statistically significant value of 
p<0.0001. In the management of uncomplicated UTIs, 
Fosfomycin should be included in empirical treatment. This 
finding is analogous with the study conducted by Ozlem 
Guneysel et al. [15]. 
CONCLUSION 
It is concluded that gram negative bacilli (E. coli) were 
responsible for majority of urinary tract infections and most of 
the strains are multidrug resistant. The drug resistance among 
uropathogens is an evolving process, therefore routine 
surveillance and clinical trials should be done regularly with the 
assistance of treating physicians to reach the most effective 
empirical treatment. 
Our findings underline the important role of 
fosfomycin in the antibacterial armamentarium for the 
treatment of UTI. Therefore a single dose of fosfomycin has 
higher efficacy and better compliance over other commonly 
prescribed drugs like (ofloxacin, nitrofurantoin) making it a 
first choice for uncomplicated lower UTI. 
We conclude that Fosfomycin is a good alternative in 
the treatment of UTI. Educating patients regarding the potential 
for resistance to the drug they are being prescribed and need 
for re-evaluation and urine culture if symptoms do not improve 
are also important. High rate of multidrug resistance was 
recorded among all isolates. 
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